Abstract
Inhibitors of estrogen-related pathways have been used with some success in the treatment of breast cancer. These include the antiestrogens tamoxifen, more recently faslodex, and the aromatase inhibitor anastrazole. However, failure and recurrence rates are substantial with drugs countering the effects of estrogens. Progestins, unlike estrogens, have generally been considered to oppose breast cancer and have been used with reasonable efficacy after antiestrogen failure. However, a building body of evidence, from cell culture, animal studies, and, most recently, several major clinical studies involving hormone replacement therapy, strongly supports the notion that progestins generally stimulate breast cancer. Our studies and those of others suggest that progestins increase the numbers of breast cancer cells by both stimulating the rate of proliferation and inhibiting cell death. These data indicate that progestin-related pathways might provide effective targets for breast cancer therapy. This review addresses the rationale for using inhibitors of progestin-related pathways to treat breast cancer and comments on some possible points of attack.
Keywords: estrogen, progestins, estrogens, aromatase
Current Cancer Drug Targets
Title: A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Volume: 4 Issue: 2
Author(s): Michael R. Moore
Affiliation:
Keywords: estrogen, progestins, estrogens, aromatase
Abstract: Inhibitors of estrogen-related pathways have been used with some success in the treatment of breast cancer. These include the antiestrogens tamoxifen, more recently faslodex, and the aromatase inhibitor anastrazole. However, failure and recurrence rates are substantial with drugs countering the effects of estrogens. Progestins, unlike estrogens, have generally been considered to oppose breast cancer and have been used with reasonable efficacy after antiestrogen failure. However, a building body of evidence, from cell culture, animal studies, and, most recently, several major clinical studies involving hormone replacement therapy, strongly supports the notion that progestins generally stimulate breast cancer. Our studies and those of others suggest that progestins increase the numbers of breast cancer cells by both stimulating the rate of proliferation and inhibiting cell death. These data indicate that progestin-related pathways might provide effective targets for breast cancer therapy. This review addresses the rationale for using inhibitors of progestin-related pathways to treat breast cancer and comments on some possible points of attack.
Export Options
About this article
Cite this article as:
Moore R. Michael, A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481515
DOI https://dx.doi.org/10.2174/1568009043481515 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Properties of Indazole Derivatives: Recent Developments
Mini-Reviews in Medicinal Chemistry Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
Current Pharmaceutical Design MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Synthesis, Molecular Docking, in vitro Antiproliferative and Antioxidant Activity of Novel Pyrrolidinyl-Carbazole Derivatives
Current Organic Synthesis The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE
Current Pharmaceutical Design The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Gallic Acid Attenuates Oleic Acid-induced Proliferation of Vascular Smooth Muscle Cell Through Regulation of AMPK-eNOS-FAS Signaling
Current Medicinal Chemistry FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Vitamin-D Receptor (VDR) Gene Polymorphisms (TaqI, FokI) in Turkish Patients with Hashimoto’s Thyroiditis: Relationship to the Levels of Vit-D and Cytokines
Endocrine, Metabolic & Immune Disorders - Drug Targets From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot Topic: ABC Transporters: Role in Modulation of Drug Pharmacokinetics and in Physiopathology and Therapeutic Perspectives (Guest Editor: Francoise Van Bambeke)]
Current Drug Targets Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products
Current Drug Targets Has the Two Week Rule Improved Cancer Detection Rates for Gastrointestinal Cancers? A Systematic Literature Review
Current Cancer Therapy Reviews Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Biocompatible Targeting Hydrogels for Breast Cancer Treatment
Mini-Reviews in Medicinal Chemistry